Press Releases
About Neumedicines
Neumedicines Inc. is a privately held, early-stage company developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology, and immunology. The company’s lead product candidate, NMIL12-1 (recombinant human interleukin-12; rHuIL-12), functions as to target multiple pathways of hematopoiesis and innate immunity and is being developed to address a broad range of clinical indications.
At Neumedicines, we are committed to developing and maximizing the scientific, clinical, and commercial potential of our product pipeline. Follow us on Twitter @Neumedicines for corporate news, events, and interests.
At Neumedicines, we are committed to developing and maximizing the scientific, clinical, and commercial potential of our product pipeline. Follow us on Twitter @Neumedicines for corporate news, events, and interests.
© 2009 Neumedicines Inc. All rights reserved.
